Deck Bio

About Deck Bio

Deck Bio is a preclinical biotechnology company developing next-generation T cell engagers for the treatment of solid tumors. The company’s platform is built around multi-pMHC targeting: a single drug designed to recognize multiple cancer-specific targets simultaneously, maintaining potency despite antigen loss or tumor heterogeneity. Deck Bio’s proprietary dbTv™ format delivers antibody-like stability and manufacturability, enabling scalable production within existing antibody infrastructure. Deck Bio is backed by Mission BioCapital, ACS BrightEdge, and Impact Ventures Partners Fund, and is supported by Bristol Myers Squibb and Servier through their Golden Ticket programs.